|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»ö-À¯¹é»ö Å©¸²Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ] |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
1. ½ÀÁø¡¤ÇǺο°±º(ÁøÇ༺ ÁöÀå°¢ÇÇÁõ, ¸¸¼º´Ü¼øÅ¼±, Àϱ¤ÇǺο°À» Æ÷ÇÔ), ¾çÁø±º(±¸ÁøµÎµå·¯±â¸¦ Æ÷ÇÔ), ¹ú·¹¹°¸°µ¥, °Ç¼±, ¼Õ¡¤¹ß¹Ù´Ú ³óÆ÷Áõ, ÆíÆòż±, È«ÇÇÁõ, ¸¸¼º¿øÆÇ»óÈ«¹Ý, ¾àÁø¡¤Áßµ¶Áø
2. ¿øÇüÅ»¸ðÁõÀÇ Ä¡·á
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
º¸Åë 1ÀÏ 2 ¡ 3ȸ Àû·®À» ȯºÎ¿¡ µµÆ÷ÇÑ´Ù.
|
| ±Ý±â |
1) ÇǺΰáÇÙ, ´Ü¼øÆ÷Áø, ¼öµÎ, ´ë»óÆ÷Áø, Á¾µÎÁø ȯÀÚ(¸é¿ª±â´É ¾ïÁ¦ÀÛ¿ë¿¡ ÀÇÇØ °¨¿°ÁõÀ» ¾ÇȽÃų ¼ö ÀÖ´Ù)
2) ÀÌ ¾à ¶Ç´Â ÀÌ ¾à ¼ººÐ¿¡ °ú¹Î¹ÝÀÀ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
3) °í¸· õ°øÀÌ ÀÖ´Â ½ÀÁø¼º ¿ÜÀ̵µ¿° ȯÀÚ(õ°øºÎÀ§ÀÇ Ä¡À¯Áö¿¬ ¹× °¨¿°ÀÇ À§ÇèÀÌ ÀÖ´Ù)
4) ±Ë¾ç(º£Ã¼Æ®º´ Á¦¿Ü), Á¦2µµ ½ÉÀ缺 ÀÌ»óÀÇ È»ó, µ¿»ó ȯÀÚ(Á¶Á÷¼öº¹, À°¾ÆÇü¼ºÀ» ¾ïÁ¦ÇÏ¿© Ä¡À¯¸¦ Áö¿¬ÇÒ ¼ö ÀÖ´Ù)
5) ¼¼±Õ, Áø±Õ, ½ºÇÇ·ÎÇìŸ, ¹ÙÀÌ·¯½º ÇǺΠ°¨¿° ȯÀÚ(¸é¿ªÀ» ¾ïÁ¦ÇÏ¿© °¨¿°ÁõÀ» ¾ÇȽÃų ¼ö ÀÖ´Ù)
|
| ½ÅÁßÅõ¿© |
´ÙÀ½°ú °°Àº »ç¶÷Àº ÀÌ ¾àÀ» »ç¿ëÇϱâ Àü¿¡ ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í.
1) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º ¹× ¼öÀ¯ºÎ
(1) ÀӺο¡ ´ëÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º¿¡ ´ëÇØ¼´Â ´ë·® ¶Ç´Â Àå±â°£¿¡ °ÉÄ£ »ç¿ëÀ» ÇÇÇÑ´Ù.
(2) ÇǺο¡ Àå±â°£, ±¤¹üÀ§ÇÏ°Ô »ç¿ë½Ã¿¡´Â ¼öÀ¯¸¦ ÇÏÁö ¾Ê´Â´Ù.
2) ¼Ò¾Æ
¼Ò¾Æ¿¡°Ô ÀÌ ¾àÀÇ Àå±â°£¿¡ °ÉÄ£ ´ë·® »ç¿ë ¶Ç´Â ¹ÐºÀºØ´ë¹ý¿¡ ÀÇÇÏ¿© ¹ßÀ°Àå¾Ö¸¦ °¡Á®¿Ã ¼ö ÀÖ´Ù. ±âÀú±Íµµ ¹ÐºÀºØ´ë¹ý°ú °°Àº ÀÛ¿ëÀ» ³ªÅ¸³¾ ¼ö ÀÖ´Ù.
3) °í·ÉÀÚ
ÀϹÝÀûÀ¸·Î °í·ÉÀÚ¿¡ »ç¿ë ½Ã ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ´ë·® ¶Ç´Â Àå±â°£ ±¤¹üÀ§ÇÏ°Ô ¹ÐºÀ¹ýÀ» »ç¿ëÇÏ´Â °æ¿ì ƯÈ÷ ÁÖÀÇÇÑ´Ù.
|
| ÀÌ»ó¹ÝÀÀ |
´ÙÀ½°ú °°Àº °æ¿ì ÀÌ ¾àÀÇ »ç¿ëÀ» Áï°¢ ÁßÁöÇϰí ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í. »ó´ã½Ã °¡´ÉÇÑÇÑ ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í.
1) ÇǺΠ°¨¿°Áõ : ÇǺÎÀÇ Áø±Õ¼º(ĵð´ÙÁõ, ¹é¼± µî), ¼¼±Õ¼º(Àü¿°¼º ³ó°¡Áø, ¸ð³¶¿° µî), ¹ÙÀÌ·¯½º¼º °¨¿°ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù[¹ÐºÀºØ´ë¹ý(ODT)ÀÇ °æ¿ì ³ªÅ¸³ª±â ½±´Ù]. ÀÌ¿Í °°Àº Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â ÀûÀýÇÑ Ç×Áø±ÕÁ¦³ª Ç×±ÕÁ¦ µîÀ» º´¿ëÇϰí Áõ»óÀÌ »¡¸® °³¼±µÇÁö ¾ÊÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
2) ±âŸ ÇǺΠÁõ»ó : Àå±â¿¬¿ë¿¡ ÀÇÇØ ½ºÅ×·ÎÀ̵强 ¿©µå¸§(½É»ó¼º ¿©µå¸§°ú ºñ½ÁÇϳª ¹é»öÀÇ ¸éÆ÷°¡ ´Ù¹ßÇÏ´Â °æÇâÀÌ ÀÖ´Ù), ½ºÅ×·ÎÀ̵强 ÇǺÎ(ÇǺÎÀ§Ãà, ¸ð¼¼Ç÷°üÈ®Àå), ½ºÅ×·ÎÀ̵强 Áֻ硤ÀÔÁÖÀ§ ÇǺο°(ÀÔÁÖÀ§ ¶§¶§·Î ¾È¸é Àüü¿¡ È«¹Ý, ±¸Áø, ¸ð¼¼Ç÷°üÈ®Àå, °¡ÇÇ, Àμ³ µîÀÌ »ý±ä´Ù), ¾î¸°¼±(åà×÷àÐ)¾ç ÇǺκ¯È, ÀÚ¹Ý, ´Ù¸ð, »ö¼ÒÅ»»ö µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â õõÈ÷ »ç¿ë·®À» ÁÙ¿© ÄÚ¸£Æ¼ÄÚÀ̵带 ÇÔÀ¯ÇÏÁö ¾ÊÀº ¾àÀ¸·Î ¹Ù²Ù¾î »ç¿ëÇÑ´Ù. µå¹°°Ô °¡·Á¿ò, Á¢ÃËÇǺο°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) °ú¹Î¹ÝÀÀ : ÇǺÎÀÇ Àڱذ¨, ¹ßÁø µîÀÇ °ú¹ÎÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
4) ³úÇϼöü¡¤ºÎ½ÅÇÇÁú°è : ´ë·® ¶Ç´Â Àå±â°£¿¡ °ÉÄ£ ±¤¹üÀ§ÇÑ »ç¿ë, ¹ÐºÀºØ´ë¹ý¿¡ ÀÇÇØ ³úÇϼöü¡¤ºÎ½ÅÇÇÁú±â´ÉÀÇ ¾ïÁ¦¸¦ °¡Á®¿Ã ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
5) ´« : ¾È°ËÇǺο¡ »ç¿ë½Ã ¾È¾Ð »ó½Â, ³ì³»ÀåÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù. ´ë·® ¶Ç´Â Àå±â°£¿¡ °ÉÃÄ ±¤¹üÀ§ÇÏ°Ô »ç¿ëÇϰųª, ƯÈ÷ ¹ÐºÀºØ´ë¹ýÀ¸·Î »ç¿ëÇÒ °æ¿ì Èij¶ÇÏ ¹é³»Àå, ³ì³»Àå µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(dexamethasone; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| Á¦Çüº° º¹¾àÁöµµ |
[Å©¸²] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Dexamethasone¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Dexamethasone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. This results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
|
| Pharmacology |
Dexamethasone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.
|
| Metabolism |
Dexamethasone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)
|
| Protein Binding |
Dexamethasone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 70%
|
| Half-life |
Dexamethasone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 36-54 hours
|
| Absorption |
Dexamethasone¿¡ ´ëÇÑ Absorption Á¤º¸ 80-90%
|
| Pharmacokinetics |
Dexamethasone propionateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´ë»çÈ¿°ú Áö¼Ó½Ã°£ : 72½Ã°£±îÁö Áö¼ÓµÉ ¼ö ÀÖ´Ù. Acetate´Â ÀÛ¿ë ¹ßÇö ½Ã°£À» ÃËÁø½ÃŲ Àå½Ã°£ Áö¼ÓÇü repository Á¦Á¦ÀÌ´Ù.
- ´ë»ç : °£¿¡¼ ´ë»ç
- ¹Ý°¨±â
- Á¤»ó ½Å±â´É : 1.8¡3.5½Ã°£
- »ý¸®Àû ¹Ý°¨±â : 36¡54½Ã°£
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£
- °æ±¸ : 1¡2½Ã°£ À̳»
- ±ÙÀ°ÁÖ»ç : 8½Ã°£ À̳»
- ¼Ò½Ç : ´¢³ª º¯À¸·Î ¹è¼³
|
| Biotransformation |
Dexamethasone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic.
|
| Toxicity |
Dexamethasone¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.
|
| Drug Interactions |
Dexamethasone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Ambenonium The corticosteroid decreases the effect of anticholinesterasesAminoglutethimide Aminogluthetimide decreases the effect of dexamethasoneAmobarbital The barbiturate decreases the effect of the corticosteroidAnisindione The corticosteroid alters the anticoagulant effectAprepitant Aprepitant increases the effect and toxicity of dexamethasoneAprobarbital The barbiturate decreases the effect of the corticosteroidAspirin The corticosteroid decreases the effect of salicylatesButabarbital The barbiturate decreases the effect of the corticosteroidButalbital The barbiturate decreases the effect of the corticosteroidButethal The barbiturate decreases the effect of the corticosteroidDicumarol The corticosteroid alters the anticoagulant effectDihydroquinidine barbiturate The barbiturate decreases the effect of the corticosteroidEdrophonium The corticosteroid decreases the effect of anticholinesterasesEthotoin The enzyme inducer decreases the effect of the corticosteroidFosphenytoin The enzyme inducer decreases the effect of the corticosteroidHeptabarbital The barbiturate decreases the effect of the corticosteroidHexobarbital The barbiturate decreases the effect of the corticosteroidImatinib Decreases levels of imatinibMephenytoin The enzyme inducer decreases the effect of the corticosteroidMethohexital The barbiturate decreases the effect of the corticosteroidMethylphenobarbital The barbiturate decreases the effect of the corticosteroidMidodrine Increased arterial pressureNeostigmine The corticosteroid decreases the effect of anticholinesterasesPentobarbital The barbiturate decreases the effect of the corticosteroidPhenobarbital The barbiturate decreases the effect of the corticosteroidPhenytoin The enzyme inducer decreases the effect of the corticosteroidPrimidone The barbiturate decreases the effect of the corticosteroidPyridostigmine The corticosteroid decreases the effect of anticholinesterasesQuinidine barbiturate The barbiturate decreases the effect of the corticosteroidRifampin The enzyme inducer decreases the effect of the corticosteroidSecobarbital The barbiturate decreases the effect of the corticosteroidSunitinib Possible decrease in sunitinib levelsTalbutal The barbiturate decreases the effect of the corticosteroidWarfarin The corticosteroid alters the anticoagulant effectBismuth The corticosteroid decreases the effect of salicylatesAcenocoumarol The corticosteroid alters the anticoagulant effectSalicylate-magnesium The corticosteroid decreases the effect of salicylatesSalsalate The corticosteroid decreases the effect of salicylates
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Dexamethasone¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food to reduce irritation.Avoid taking with grapefruit juice.
|
| Drug Target |
[Drug Target]
|
| Description |
Dexamethasone¿¡ ´ëÇÑ Description Á¤º¸ An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]
|
| Dosage Form |
÷°¡Á¦1 º¥Áú¾ËÄÚ¿Ã (ÁÖ»çÁ¦¿¡ ÇÑÇÔ.) ¡Û °æ°í
º¥Áú¾ËÄÚ¿ÃÀº ¹Ì¼÷¾Æ¿¡¼ Ä¡¸íÀûÀÎ °¡»Û È£ÈíÁõ»ó°ú ¿¬°üÀÌ ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ¾ú´Ù.
¡Û ´ÙÀ½ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¸» °Í.
½Å»ý¾Æ, ¹Ì¼÷¾Æ(º¥Áú¾ËÄÚ¿ÃÀ» ÇÔÀ¯Çϰí ÀÖ´Ù.)
|
| Drug Category |
Dexamethasone¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic AgentsAnti-inflammatory AgentsAntiemeticsAntineoplastic Agents, HormonalGlucocorticoids
|
| Smiles String Canonical |
Dexamethasone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
|
| Smiles String Isomeric |
Dexamethasone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
|
| InChI Identifier |
Dexamethasone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
|
| Chemical IUPAC Name |
Dexamethasone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
|
| Drug-Induced Toxicity Related Proteins |
DEXAMETHASONE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Brain-cadherin (BR-cadherin) Drug:dexamethasone Toxicity:osteoblast differentiation. [¹Ù·Î°¡±â] Replated Protein:Glucocorticoid-induced leucine zipper (GILZ) Drug:dexamethasone Toxicity:apoptosis. [¹Ù·Î°¡±â] Replated Protein:Signal transducer and activator of transcription 3 Drug:dexamethasone Toxicity:apoptosis. [¹Ù·Î°¡±â] Replated Protein:Heme oxygenase 1 Drug:dexamethasone Toxicity:oxidative injury. [¹Ù·Î°¡±â] Replated Protein:Alkaline phosphatase Drug:dexamethasone Toxicity:osteoblast differentiation. [¹Ù·Î°¡±â] Replated Protein:Interleukin-6 Drug:dexamethasone Toxicity:apoptosis. [¹Ù·Î°¡±â] Replated Protein:Ornithine decarboxylase Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers. [¹Ù·Î°¡±â] Replated Protein:Aromatic-L-amino-acid decarboxylase Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers. [¹Ù·Î°¡±â] Replated Protein:Interleukin-4 Drug:dexamethasone Toxicity:dexamethasone-induced differentiation of mouse myeloid leukemia cells. [¹Ù·Î°¡±â] Replated Protein:Gastrin Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers. [¹Ù·Î°¡±â] Replated Protein:Interleukin-4 Drug:dexamethasone Toxicity:dexamethasone-induced differentiation of mouse myeloid leukemia cells. [¹Ù·Î°¡±â] Replated Protein:Cadherin-11 Drug:dexamethasone Toxicity:osteoblast differentiation. [¹Ù·Î°¡±â] Replated Protein:Haptoglobin Drug:dexamethasone Toxicity:hepatic lipidosis(fatty liver). [¹Ù·Î°¡±â] Replated Protein:Interferon alpha-7 Drug:dexamethasone Toxicity:apoptosis. [¹Ù·Î°¡±â] Replated Protein:C-jun-amino-terminal kinase-interacting protein Drug:dexamethasone Toxicity:apoptosis of multiple myeloma cells. [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase Drug:dexamethasone Toxicity:Dex-induced apoptosis. [¹Ù·Î°¡±â] Replated Protein:Cadherin-4 Drug:dexamethasone Toxicity:osteoblast differentiation. [¹Ù·Î°¡±â] Replated Protein:Glucose transporter 4 Drug:dexamethasone Toxicity:cushing's syndrome. [¹Ù·Î°¡±â] Replated Protein:Nuclear factor NF-kappa-B Drug:dexamethasone Toxicity:pulmonary inflammation. [¹Ù·Î°¡±â] Replated Protein:Signal transducer and activator of transcription 3 Drug:dexamethasone Toxicity:oxidative injury such as endotoxins and heme. [¹Ù·Î°¡±â] Replated Protein:Thrombomodulin Drug:dexamethasone Toxicity:deep venous thrombosis (DVT). [¹Ù·Î°¡±â] Replated Protein:Islet amyloid polypeptide Drug:dexamethasone Toxicity:marked stimulatory effect. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2020-05-08
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. DEXAMETHASONE[GGT Increase][Composite Activity](Score) NA(Marginal) 0(Active) 0[Alkaline Phosphatase Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[SGOT Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[SGPT Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[LDH Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[GGT Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|